Skip to content

Study · Randomized controlled trial · n = 371 · 2024

3 results

Immune-Enhancing Treatment among Acute Necrotizing Pancreatitis Patients with Metabolic Abnormalities: A Post Hoc Analysis of a Randomized Clinical Trial.

Huang X, Mao W, Hu X, Qin F, Zhao H, Zhang A, Wang X, Stoppe C, Zhou D, Ke L, Ni H

Gut and liver15 Feb 2024Cited by 2 (Europe PMC)

PMID38356344 (opens in a new tab)PMCIDPMC11391137 (opens in a new tab)DOI10.5009/gnl230326 (opens in a new tab)PepBankPUB-38356344
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with acute necrotizing pancreatitis and hypertriglyceridemia, thymosin alpha‑1 was not associated with a lower incidence of 90-day infected pancreatic necrosis.

    In plain wordsIn people with severe pancreatitis and high blood fats, thymosin alpha‑1 was not linked to fewer infected necrosis cases than placebo.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant change90-day infected pancreatic necrosis (IPN) in patients with hypertriglyceridemia
    Study

    n = 371

    Comparator
    Matching placebo
    Analysis
    Exploratory
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    but not in the other subgroups.
    2 context sentences
    Summary · context
    Among them, 271 (54.0%) had hyperglycemia, 371 (73.9%) had hypertriglyceridemia and 229 (45.6%) had both.
    Summary · context
    Overall, 502 participants were included in this post hoc analysis (248 received Tα1 treatment and 254 received matching placebo treatment).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with acute necrotizing pancreatitis and hyperglycemia, thymosin alpha‑1 was associated with a lower incidence of 90-day infected pancreatic necrosis than placebo.

    In plain wordsIn people with severe pancreatitis and high blood sugar, thymosin alpha‑1 was linked to fewer infected necrosis cases than placebo, in a post hoc subgroup.

    Peptide
    Thymosin alpha-1
    Outcome
    Decrease90-day infected pancreatic necrosis (IPN) in patients with hyperglycemia
    Study

    n = 271

    Comparator
    Matching placebo
    Analysis
    Exploratory
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated

    Measurements

    HR
    0.8
    hyperglycemia subgroup

    Source sentences

    Summary
    Tα1 therapy was associated with reduced incidence of IPN among patients with hyperglycemia (18.8% vs 29.7%: hazard ratio, 0.80; 95% confidence interval, 0.37 to 0.97; p=0.03)
    2 context sentences
    Summary · context
    Among them, 271 (54.0%) had hyperglycemia, 371 (73.9%) had hypertriglyceridemia and 229 (45.6%) had both.
    Summary · context
    Overall, 502 participants were included in this post hoc analysis (248 received Tα1 treatment and 254 received matching placebo treatment).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with acute necrotizing pancreatitis and both hyperglycemia and hypertriglyceridemia, thymosin alpha‑1 was not associated with a lower incidence of 90-day infected pancreatic necrosis.

    In plain wordsIn people with severe pancreatitis and high blood sugar and high blood fats, thymosin alpha‑1 was not linked to fewer infected necrosis cases than placebo.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant change90-day infected pancreatic necrosis (IPN) in patients with both hyperglycemia and hypertriglyceridemia
    Study

    n = 229

    Comparator
    Matching placebo
    Analysis
    Exploratory
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    but not in the other subgroups.
    2 context sentences
    Summary · context
    Among them, 271 (54.0%) had hyperglycemia, 371 (73.9%) had hypertriglyceridemia and 229 (45.6%) had both.
    Summary · context
    Overall, 502 participants were included in this post hoc analysis (248 received Tα1 treatment and 254 received matching placebo treatment).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT02473406

Thymosin Alpha 1 in the Prevention of Pancreatic Infection Following Acute Necrotizing Pancreatitis

Weiqin Lin = 50827 Mar 2018 to 24 Mar 2021

Pancreatitis, Acute Necrotizing

Trial pageClinicalTrials.govUpdated 5 Apr 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.